Company intelligence / Profile preview

Auxilius Pharma

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Auxilius Pharma has completed a Phase 1a first-in-human trial for AUX-001, showing positive safety profile results. The study demonstrated extended half-life of nicorandil from about 50 minutes to over 9 hours, enabling once-daily dosing. The company plans to file an IND application and initiate a Phase 1b bioequivalence study with approximately 35 healthy volunteers in Q4 2024 or early Q1 2025, followed by a Phase 3 trial in H2 2025[6][9].

Therapeutic areas: Cardiovascular
Modalities: Small molecules (specifically extended-release formulations)
Industry: Biotech

Drug pipeline

2 assets

AUX-002

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Auxilius Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auxilius Pharma.

Explore the full profile